非动脉样硬化再生血管高血压
Jessie Dalman1, Dawn M Coleman2
1University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI, USA.
The Surgical clinics of North America
|July 16, 2023
概括
血管高血压 (RVH) 是由脏动脉阻塞引起的高血压. 这种情况可以通过解决潜在的动脉封闭性疾病来纠正.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心血管医学 心血管医学
- 内分泌学 在内分泌学.
背景情况:
- 血管高血压 (RVH) 是血压升高的次要原因.
- 它源于动脉血流减少,激活氨酸-血管氨酸-氨酸系统.
- 这种情况往往是可纠正的,通常是由于动脉封闭性疾病.
研究的目的:
- 阐明血管高血压的病理生理机制.
- 详细介绍RVH所涉及的荷尔蒙和血管路径.
- 要突出氨酸- ангиотензин- алдостерон系统在RVH中的作用.
主要方法:
- 通过脏低输液启动的生理级联的审查.
- 激素信号通路的分析,涉及氨酸,血管新生素II和阿尔多斯特.
- 检查血管和脏的血管和血管II的作用.
主要成果:
- 降低动脉压力会触发氨酸的释放,从而启动氨酸- ангиотензин- 阿尔多素级联.
- ангиотензин II 引起血管收缩,/水再吸收和交感激活,增加血压.
- 阿尔多的释放和血管压素的分泌进一步导致体积膨胀和血管收缩.
结论:
- RVH是一种复杂的疾病,由氨酸- ангиотензин-阿尔多斯特系统和 ангиотензин II 作用驱动.
- 了解这些机制对于管理和潜在地纠正RVH至关重要.
- 血管素II的多方面的作用最终导致持续的高血压.
相关概念视频
01:29Hypertension II: Pathophysiology
20
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
20
01:25Antihypertensive Drugs: Direct Renin Inhibitors
697
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
697
01:18Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
696
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
696
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
786
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
786
01:23Antihypertensive Drugs: Vasodilators
573
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
573